Russian law subjects shell company structures with Russian elements in the pharmaceuticals sector to a layered unwinding framework that combines general corporate veil provisions, sham transaction doctrine, and sector-specific pharmaceutical licensing rules – and foreign creditors who approach recovery without accounting for all three layers typically encounter significant procedural obstacles.
Under Russian civil and corporate legislation, courts may disregard the separate legal personality of an intermediate holding entity where it is found to be a conduit with no genuine independent commercial function. The governing doctrine – commonly described in Russian legal practice as the "lifting of the corporate veil" – requires the claimant to demonstrate that the intermediate entity was used to conceal the true beneficial owner or to shield assets from creditors. This threshold is not easily met and typically demands contemporaneous documentary evidence of control, funds flows, and decision-making. Where a transaction forming part of the shell structure can be characterised as a sham under Russian law, courts have the power to declare it void and restore the parties to their prior positions – subject to bona fide third-party purchaser protections that frequently complicate asset recovery.
In the pharmaceuticals sector, an additional dimension arises: pharmaceutical licences, marketing authorisations, and registration certificates held by a Russian entity cannot be transferred or re-attributed to a creditor or liquidator as an incidental consequence of unwinding the ownership structure. The regulatory authority responsible for pharmaceutical oversight in Russia – Roszdravnadzor – retains control over licence continuity, and any restructuring that touches the licensed entity requires advance regulatory engagement. For a foreign creditor seeking to recover value from a pharmaceutical distributor or manufacturer, this means the recoverable asset pool may be practically constrained even where the unwinding claim itself succeeds.
Foreign creditors should therefore conduct a two-stage assessment before commencing any unwinding proceedings: first, map the full ownership chain to identify where Russian-law entities sit and what assets are held at each level; second, obtain an early-stage analysis of whether pharmaceutical licences constitute a material share of the target's value and what regulatory steps would be required to preserve that value through the recovery process. Delay in initiating proceedings can erode both the strength of the unwinding claim and the practical recoverability of pharmaceutical assets if licence continuity lapses.
If you are a foreign creditor tracing assets through a Russian-element shell structure in the pharmaceutical sector, the firm's asset tracing and recovery practice can provide an initial assessment of the unwinding framework applicable to your matter: info@vetrovpartners.com | WhatsApp / Telegram: +7 (983) 510-38-76
— Elizaveta Razina Senior Lawyer, Practice Lead — IP Enforcement, Vetrov & Partners vetrovpartners.com/razina/
Elizaveta Razina leads the firm's intellectual property practice, representing foreign trademark owners in infringement proceedings before Russian state courts and the IP Court. She has been with the firm since 2012 and holds a degree from Novosibirsk State University (2013). She advises on anti-counterfeiting strategy, parallel import controls, and, in conjunction with the firm's asset tracing practice, on asset recovery matters involving IP-adjacent structures.
This publication is provided for informational purposes only and does not constitute legal advice under Russian or any other applicable law. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Vetrov & Partners is a Russian-qualified law firm. For matters governed by foreign law or requiring local admission in another jurisdiction, we collaborate with trusted counsel in the relevant jurisdiction. For advice regarding your particular situation, please contact info@vetrovpartners.com.